Simvastatin-loaded macroporous calcium phosphate cement: Preparation, in vitro characterization, and evaluation of in vivo performance

Journal of Biomedical Materials Research - Part A

Volumn 100 A, Issue 11, 2012, Pages 2991-3000

  Yin, Han ^a,b   Li, Yong Gang ^b   Si, Meng ^b   Li, Jian Min ^b  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Calcium phosphate bone cements; Drug delivery systems; Simvastatin; Sodium dodecyl sulfate

Indexed keywords

BIOCOMPATIBILITY; BONE CEMENT; CALCIUM PHOSPHATE; CHEMICAL PROPERTIES; DRUG DELIVERY; HYDROXYAPATITE; SODIUM;

AIR ENTRAINING AGENTS; BIOLOGICAL PROPERTIES; CALCIUM PHOSPHATE BONE CEMENT; CALCIUM PHOSPHATE CEMENT; DRUG DELIVERY SYSTEM; IN-VITRO; IN-VIVO; INFLAMMATORY REACTION; INITIAL SETTING TIME; LIQUID PHASE; MACROPORES; MACROPOROUS; MECHANICAL CHARACTERISTICS; OSTEOGENIC POTENTIAL; PHYSICOCHEMICAL PROPERTY; SIMVASTATIN; SODIUM DODECYL SULFATE; SOLID-PHASE; TEST SAMPLES;

SODIUM SULFATE;

BONE CEMENT; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; DODECYL SULFATE SODIUM; HYDROXYAPATITE; SIMVASTATIN; TETRACALCIUM PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BONE DEVELOPMENT; BONE IMPLANT; COMPRESSIVE STRENGTH; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RELEASE; EXPERIMENTAL RABBIT; HISTOLOGY; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIQUID; LOW DRUG DOSE; MATERIALS TESTING; MUSCLE NECROSIS; NONHUMAN; PHASE TRANSITION; PHYSICAL CHEMISTRY; POROSITY; RATING SCALE; SCANNING ELECTRON MICROSCOPY; SOLID; X RAY DIFFRACTION;

EID: 84869092261     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34228     Document Type: Article

References (44)

1. Ambard AJ, Mueninghoff L. Calcium phosphate cement: Review of mechanical and biological properties. J Prosthodont 2006;15:321-328. (Pubitemid 44337428)
2. Takagi S, Chow LC. Formation of macropores in calcium phosphate cement implants. J Mater Sci Mater Med 2001;12:135-139. (Pubitemid 32178863)
3. Chow LC. Next generation calcium phosphate-based biomaterials. Dent Mater J 2009;28:1-10.
4. del Real RP, Wolke JGC, Vallet-Regi M, Jansen JA. A new method to produce macropores in calcium phosphate cements. Biomaterials 2002;23:3673-3680. (Pubitemid 34626570)
5. Montufar EB, Traykova T, Schacht E, Ambrosio L, Santin M, Planell JA, Ginebra MP. Self-hardening calcium deficient hydroxyapatite/gelatine foams for bone regeneration. J Mater Sci Mater Med 2010;21:863-869.
6. Ginebra MP, Espanol M, Montufar EB, Perez RA, Mestres G. New processing approaches in calcium phosphate cements and their applications in regenerative medicine. Acta Biomater 2010;6:2863-2873.
7. Sarda S, Nilsson M, Balcells M, Fernandez E. Influence of surfactant molecules as air-entraining agent for bone cement macroporosity. J Biomed Mater Res A 2003;65:215-221. (Pubitemid 37526680)
8. Bodde EW, Boerman OC, Russel FG, Mikos AG, Spauwen PH, Jansen JA. The kinetic and biological activity of different loaded rhBMP-2 calcium phosphate cement implants in rats. J Biomed Mater Res A 2008;87:780-791.
9. Ohura K, Hamanishi C, Tanaka S, Matsuda N. Healing of segmental bone defects in rats induced by a beta-TCP-MCPM cement combined with rhBMP-2. J Biomed Mater Res 1999;44:168-175. (Pubitemid 28566805)
10. Blumenthal NM, Koh-Kunst G, Alves ME, Miranda D, Sorensen RG, Wozney JM, Wikesjo UM. Effect of surgical implantation of recombinant human bone morphogenetic protein-2 in a bioabsorbable collagen sponge or calcium phosphate putty carrier in intrabony periodontal defects in the baboon. J Periodontol 2002;73:1494-1506. (Pubitemid 36131621)
11. Ruhe PQ, Kroese-Deutman HC, Wolke JG, Spauwen PH, Jansen JA. Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants in cranial defects in rabbits. Biomaterials 2004;25:2123-2132. (Pubitemid 38102412)
12. Li M, Liu XY, Liu XD, Ge BF. Calcium phosphate cement with BMP-2-loaded gelatin microspheres enhances bone healing in osteoporosis: A pilot study. Clin Orthopaed Relat Res 2010;468:1978-1985.
13. Einhorn TA. Clinical applications of recombinant human BMPs: Early experience and future development. J Bone Joint Surg Am 2003;85-A (Suppl 3): 82-88. (Pubitemid 36957902)
14. Hunninghake DB. Therapeutic efficacy of the lipid-lowering armamentarium: The clinical benefits of aggressive lipid-lowering therapy. Am J Med 1998;104:9S-13S. (Pubitemid 28166571)
15. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949. (Pubitemid 129515901)
16. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000;271:688-692. (Pubitemid 30444689)
17. Ho ML, Chen YH, Liao HJ, Chen CH, Hung SH, Lee MJ, Fu YC, Wang YH, Wang GJ, Chang JK. Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 2009;39:296-303.
18. Rutledge J, Schieber MD, Chamberlain JM, Byarlay M, Killeen AC, Giannini PJ, Marx DB, Reinhardt RA. Simvastatin application to augment facial jaw bone in a dog model: Pilot study. J Periodontol 2011;82:597-605.
19. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211-3216. (Pubitemid 30422038)
20. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMGCoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-3210. (Pubitemid 30422037)
21. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA. Use of statins and fracture: Results of 4 prospective studies and cumulative meta-Analysis of observational studies and controlled trials. Arch Intern Med 2004;164:146-152. (Pubitemid 38140400)
22. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355:2218-2219. (Pubitemid 30394332)
23. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000;85:1137-1142. (Pubitemid 32269362)
24. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 2001;86:4556-4559. (Pubitemid 32848589)
25. Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, Lucani B, Gennari C. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: A 1-year longitudinal study. Bone 2003;32:427-433. (Pubitemid 36410317)
26. Wong RWK, Rabie ABM. Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg 2003;41:244-248. (Pubitemid 37184465)
27. Nyan M, Sato D, Oda M, Machida T, Kobayashi H, Nakamura T, Kasugai S. Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect. J Pharmacol Sci 2007;104:384-386. (Pubitemid 47378426)
28. Nyan M, Sato D, Kihara H, Machida T, Ohya K, Kasugai S. Effects of the combination with alpha-tricalcium phosphate and simvastatin on bone regeneration. Clin Oral Implants Res 2009;20:280-287.
29. Nyan M, Miyahara T, Noritake K, Hao J, Rodriguez R, Kuroda S, Kasugai S. Molecular and tissue responses in the healing of rat calvarial defects after local application of simvastatin combined with alpha tricalcium phosphate. J Biomed Mater Res B Appl Biomater 2010;93:65-73.
30. Link DP, van den Dolder J, van den Beucken JJ, Cuijpers VM, Wolke JG, Mikos AG, Jansen JA. Evaluation of the biocompatibility of calcium phosphate cement/PLGA microparticle composites. J Biomed Mater Res A 2008;87:760-769.
31. Link DP, van den Dolder J, van den Beucken JJ, Wolke JG, Mikos AG, Jansen JA. Bone response and mechanical strength of rabbit femoral defects filled with injectable CaP cements containing TGF-beta 1 loaded gelatin microparticles. Biomaterials 2008;29:675-682. (Pubitemid 350181047)
32. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des 2001;7:715-736. (Pubitemid 32427770)
33. Hirsch D, Drader J, Thomas TJ, Schoen FJ, Levy JT, Levy RJ. Inhibition of calcification of glutaraldehyde pretreated porcine aortic valve cusps with sodium dodecyl sulfate: Preincubation and controlled release studies. J Biomed Mater Res 1993;27:1477-1484. (Pubitemid 23341474)
34. Ruddy SB, Matuszewska BK, Grim YA, Ostovic D, Storey DE. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. Int J Pharm 1999;182:173-186. (Pubitemid 29248846)
35. Dhiman MK, Dhiman A, Sawant KK. Transbuccal delivery of 5-fluorouracil: Permeation enhancement and pharmacokinetic study. AAPS Pharm Sci Tech 2009;10:258-265.
36. Li M, Liu X, Ge B, Chen K. Creation of macroporous calcium phosphate cements as bone substitutes by using genipin-crosslinked gelatin microspheres. J Mater Sci Mater Med 2009;20:925-934.
37. Margulis-Goshen K, Magdassi S. Formation of simvastatin nanoparticles from microemulsion. Nanomedicine 2009;5:274-281.
38. Lebugle A, Sarda S, Heughebaert M. Influence of the type of surfactant on the formation of calcium phosphate in organized molecular systems. Chem Mater 1999;11:2722-2727. (Pubitemid 129692349)
39. Habraken WJEM, Liao HB, Zhang Z, Wolke JGC, Grijpma DW, Mikos AG, Feijen J, Jansen JA. In vivo degradation of calcium phosphate cement incorporated into biodegradable microspheres. Acta Biomater 2010;6:2200-2211.
40. Thompson PD, Clarkson P, Karas RH. Statin-Associated myopathy. JAMA 2003;289:1681-1690. (Pubitemid 37430274)
41. Mullen PJ, Luscher B, Scharnagl H, Krahenbuhl S, Brecht K. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol 2010;79:1200-1209.
42. Rojbani H, Nyan M, Ohya K, Kasugai S. Evaluation of the osteoconductivity of alpha-tricalcium phosphate, beta-tricalcium phosphate, and hydroxyapatite combined with or without simvastatin in rat calvarial defect. J Biomed Mater Res A 2011;98:488-498.
43. Adah F, Benghuzzi H, Tucci M, Russell G, England B. Effects of sustained release of statin by means of tricalcium phosphate lysine delivery system in defect and segmental femoral injuries on certain biochemical markers in vivo. Biomed Sci Instrum 2006;42:126-135.
44. Kroese-Deutman HC, Wolke JG, Spauwen PH, Jansen JA. Closing capacity of cranial bone defects using porous calcium phosphate cement implants in a rabbit animal model. J Biomed Mater Res A 2006;79:503-511. (Pubitemid 44845163)